The effect of changing from whole-cell to acellular pertussis vaccine on the epidemiology of hospitalized children with pertussis in Canada

Pediatric Infectious Disease Journal

Volumn 26, Issue 1, 2007, Pages 31-35

  Bettinger, Julie A ^a,e   Halperin, Scott A ^b   De Serres, Gaston ^c   Scheifele, David W ^a   Tam, Theresa ^d  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

^c INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

^d PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^e BC CHILDREN S HOSPITAL   (Canada)

Author keywords

Acellular; Children; Pertussis; Vaccine; Whole cell

Indexed keywords

PERTUSSIS VACCINE;

ADOLESCENT; ARTICLE; BORDETELLA PERTUSSIS; CANADA; CHILD; DRUG EFFECT; FEMALE; HOSPITALIZATION; HUMAN; IMMUNIZATION; INFANT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NEWBORN; PEDIATRIC HOSPITAL; PERTUSSIS; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; TERTIARY HEALTH CARE; VACCINATION;

ADOLESCENT; BORDETELLA PERTUSSIS; CANADA; CHILD; CHILD, HOSPITALIZED; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; PERTUSSIS VACCINE; VACCINES, ACELLULAR; WHOOPING COUGH;

EID: 33846013966     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000247055.81541.04     Document Type: Article

References (30)

1. Varughese P. Incidence of pertussis in Canada. CMAJ. 1985;132:1041-1042.
2. Marchessault V, ed. Canadian Immunization Guide, Sixth Edition. Ottawa, Canada: Canadian Medical Association; 2002.
3. Ntezayabo B, De Serres G, Duval B. Pertussis resurgence in Canada largely caused by a cohort effect. Pediatr Infect Dis J. 2003;22:22-27.
4. Halperin SA, Bortolussi R, MacLean D, Chisholm N. Persistence of pertussis in an immunized population: results of the Nova Scotia Enhanced Pertussis Surveillance Program. J Pediatr. 1989;115(5 pt 1):686-693.
5. De Serres G, Boulianne N, Duval B, et al. Effectiveness of a whole cell pertussis vaccine in child-care centers and schools. Pediatr Infect Dis J. 1996;15:519-524.
6. Bentsi-Enchill AD, Halperin SA, Scott J, MacIsaac K, Duclos P. Estimates of the effectiveness of a whole-cell pertussis vaccine from an outbreak in an immunized population. Vaccine. 1997;15:301-306.
7. De Serres G, Boulianne N, Duval B. Field effectiveness of erythromycin prophylaxis to prevent pertussis within families. Pediatr Infect Dis J. 1995;14:969-975.
8. NACI. Prevention of pertussis in adolescents and adults. Can Commun Dis Rep. 2003;29:1-9.
9. Capiau C, Poolman J, Hoet B, Bogaerts H, Andre F. Development and clinical testing of multivalent vaccines based on a diphtheria-tetanus-acellular pertussis vaccine: difficulties encountered and lessons learned. Vaccine. 2003;21:2273-2287.
10. Blennow M, Granstrom M. Adverse reactions and serologic response to a booster dose of acellular pertussis vaccine in children immunized with acellular or whole-cell vaccine as infants. Pediatrics. 1989;84:62-67.
11. Halperin SA, Eastwood B, Barreto L, et al. Safety and immunogenicity of two acellular pertussis vaccines with different pertussis toxoid and filamentous hemagglutinin content in infants 2-6 months old. Scand J Infect Dis. 1995;27:279-287.
12. Halperin SA, Smith B, Russell M, et al. An adult formulation of a five-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids is safe and immunogenic in adolescents and adults. Vaccine. 2000;18:1312-1319.
13. Scheifele DW, Halperin SA, Gold R, Samson H, King A. Assuring vaccine safety: a celebration of 10 years of progress with the IMPACT project. Paediatr Child Health. 2002;7:645-648.
14. Halperin SA, Wang EE, Law B, et al. Epidemiological features of pertussis in hospitalized patients in Canada, 1991-1997: report of the Immunization Monitoring Program-Active (IMPACT). Clin Infect Dis. 1999;28:1238-1243.
15. Glare EM, Paton JC, Premier RR, Lawrence AJ, Nisbet IT. Analysis of a repetitive DNA sequence from Bordetella pertussis and its application to the diagnosis of pertussis using the polymerase chain reaction. J Clin Microbiol. 1990;28:1982-1987.
16. Notifiable diseases summary. Can Commun Dis Rep. 2001;27 (S6).
17. Notifiable diseases summary. Can Commun Dis Rep. 2004;30 (21).
18. Notifiable diseases summary. Can Commun Dis Rep. 2005;31 (22).
19. McWha L, MacArthur A, Badiani T, et al. Measuring up: results from the national immunization coverage survey, 2002. Can Commun Dis Rep. 2004;30 (5).
20. World Health Organization. Pertussis vaccines. Wkly Epidemiol Rec. 1999;74:137-143.
21. Grimprel E, Baron S, Levy-Bruhl D, et al. Influence of vaccination coverage on pertussis transmission in France. Lancet. 1999;354:1699-1700.
22. Baron S, Njamkepo E, Grimprel E, et al. Epidemiology of pertussis in French hospitals in 1993 and 1994: thirty years after a routine use of vaccination. Pediatr Infect Dis J. 1998;17:412-418.
23. Izurieta HS, Kenyon TA, Strebel PM, et al. Risk factors for pertussis in young infants during an outbreak in Chicago in 1993. Clin Infect Dis. 1996;22:503-507.
24. Kandola K, Lea A, White W, Santos M. A comparison of pertussis rates in the Northwest Territories: pre- and postacellular pertussis vaccine introduction in children and adolescents. Can J Infect Dis Med Microbiol. 2005;16:271-274.
25. Edwards KM. Pertussis: an important target for maternal immunization. Vaccine. 2003;21:3483-3486.
26. Healy CM, Munoz FM, Rench MA, et al. Prevalence of pertussis antibodies in maternal delivery, cord, and infant serum. J Infect Dis. 2004;190:335-340.
27. Tanaka M, Vitek CR, Pascual FB, et al. Trends in pertussis among infants in the United States, 1980-1999. JAMA. 2003;290:2968-2975.
28. Vitek CR, Pascual FB, Baughman AL, Murphy TV. Increase in deaths from pertussis among young infants in the United States in the 1990s. Pediatr Infect Dis J. 2003;22:628-634.
29. Bisgard KM, Rhodes P, Connelly BL, et al. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001. Pediatrics. 2005;116:e285-294.
30. National Advisory Committee on Immunization. An advisory committee statement (ACS): National Advisory Committee on Immunization (NACI): Interval between administration of vaccines against diphtheria, tetanus, and pertussis. Can Commun Dis Rep. 2005;31:17-22.